Assistant Professor, DeGroote School of Business, Strategic Market Leadership & Health Services Management
Member, Centre for Health Economics and Policy Analysis

Christopher Longo has 16 years of industry experience in clinical research, economic evaluation, and market access strategies for pharmaceuticals. He has published both clinical and economic research in a number of therapeutic areas including diabetes, cancer, sepsis and central nervous system disorders. His research interests include the economic and quality of life evaluation of pharmaceuticals in the areas of cancer, diabetes and sepsis, global pharmaceutical pricing strategies, the public/private mix in the financing of healthcare, the evaluation of factors influencing patients’ financial burden for health care services, and factors that lead to higher individual consumption of health care resources. Longo has consulted with numerous provincial and federal agencies related to economic evaluation of pharmaceuticals including: the Canadian Agency for Drugs and Technology in Health (formerly Canadian Co-ordinating Office for Health Technology Assessment), Cancer Care Ontario, Ontario Ministry of Health and Long Term Care, and the National Cancer Institute of Canada. Longo was the past chair of Rx&D’s (Canada’s Research-Based Pharmaceutical Companies) Health Economic Working Group from 2002-2004. Longo has also acted as an expert advisor to a number of Rx&D committees from 1997 to 2005. He is a reviewer for the journals Pharmacoeconomics, Medical Care, Canadian Medical Association Journal, and Supportive Care in Cancer.

RESEARCH INTERESTS

• cost effectiveness, cost utility, and quality of life analysis in the areas of cancer, diabetes, and sepsis.
• evaluating strategies associated with global pharmaceutical pricing.
• understanding patients’ financial burden associated with health care, and the role of the state.
• understanding the factors that lead to higher individual consumption of health care resources.

REPRESENTATIVE PUBLICATIONS

Longo CJ, Heyland DK, Fisher HN, Fowler RA, Martin C, Day A. A long term follow-up study investigating health related quality of life and resource use in survivors of severe sepsis: Comparison of recombinant human activated protein C to standard care.  Critical Care, 2007; 11(6): R128

Longo CJ, Deber R, Fitch M, Williams P. DeSouza D. An examination of cancer patients’ monthly “out-of-pocket” costs in Ontario. European Journal of Cancer Care, 2007; 16: 500-507

Longo CJ,  Deber R,  Fitch M, Williams AP. Financial and Family Burden associated with Cancer Treatment in Ontario. Supportive Care in Cancer, Nov 2006; 14: 1077-1085

Grossman L, Longo CJ. Economic benefits of pioglitazone for treating patients with Type 2 diabetes.  Expert Review of Pharmacoeconomics & Outcomes Research, April 2004; 4(2), 135-142

LeTarte  J, Longo CJ, Pelletier J, Nabonne B, Fisher H.  Patient Characteristics and Costs of Severe Sepsis and Septic Shock in Quebec. Journal of Critical Care, Mar 2002; 7(1): 39-49

TEACHING ACTIVITIES

• Health economics and evaluation (MBA)
• Population health management (MBA)
• Pharma/Biotech business issues (MBA)
• Canadian health policy and health economics (Commerce undergraduate)